Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02960594 · ClinicalTrials.gov registry record · Phase 1
hTERT Immunotherapy Alone or in Combination With IL-12 DNA Followed by Electroporation in Adults With Solid Tumors at High Risk of Relapse
A Phase 1 study, sponsored by Inovio Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 93
- Enrollment target
NCT02960594 is a Phase 1 study that has completed, run by Inovio Pharmaceuticals. The registered enrollment target is 93 participants.
The verdict
NCT02960594, a Phase 1 study, has completed, sponsored by Inovio Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 93 participants
- Enrollment target
Study Summary
This is a Phase I, open label study to evaluate the safety, tolerability, and immunogenicity of INO-1400 or INO-1401 alone or in combination with INO-9012, delivered by electroporation in subjects with high-risk solid tumor cancer with no evidence of disease after surgery and standard therapy. Subjects will be enrolled into one of ten treatment arms. Subjects will be assessed according to standard of care. Restaging and imaging studies will be performed to assess disease relapse per NCCN guidelines. RECIST will be used to validate the findings in cases of relapse.
Interventions
- BIOLOGICAL INO-9012
- BIOLOGICAL INO-1400
- BIOLOGICAL INO-1401
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 93 participants |
| Start Date | 2014-12 |
| Est. Completion | 2018-11-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02960594
The ClinicalTrials.gov registry entry for NCT02960594 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 93 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Inovio Pharmaceuticals, which has 28 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which INO-9012 is the first listed.
NCT02960594 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02960594 about?
NCT02960594 is a clinical study titled "hTERT Immunotherapy Alone or in Combination With IL-12 DNA Followed by Electroporation in Adults With Solid Tumors at High Risk of Relapse". This is a Phase I, open label study to evaluate the safety, tolerability, and immunogenicity of INO-1400 or INO-1401 alone or in combination with INO-9012, delivered by electroporation in subjects with high-risk solid tumor cancer with no evidence of disease after surgery and standard therapy. Subje...
What is the current status of trial NCT02960594?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 93 participants. The study started on 2014-12. Estimated completion is 2018-11-09.
What interventions are being tested in trial NCT02960594?
The interventions under investigation include: INO-9012 (BIOLOGICAL), INO-1400 (BIOLOGICAL), INO-1401 (BIOLOGICAL).
Who is sponsoring clinical trial NCT02960594?
This trial is sponsored by Inovio Pharmaceuticals, which has 28 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.